WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H206450
CAS#: 1448428-04-3 (free base)
Description: Selonsertib, also known as GS-4997, is an orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities. GS-4997 targets and binds to the catalytic kinase domain of ASK1 in an ATP-competitive manner, thereby preventing its phosphorylation and activation. GS-4997 prevents the production of inflammatory cytokines, down-regulates the expression of genes involved in fibrosis, suppresses excessive apoptosis and inhibits cellular proliferation.
Hodoodo Cat#: H206450
Name: Selonsertib free base
CAS#: 1448428-04-3 (free base)
Chemical Formula: C24H24FN7O
Exact Mass: 445.20
Molecular Weight: 445.500
Elemental Analysis: C, 64.71; H, 5.43; F, 4.26; N, 22.01; O, 3.59
Related CAS #: 1448428-04-3 (free base) 1448428-05-4 (HCl)
Synonym: GS-4997; GS4997; GS 4997; Selonsertib free base.
IUPAC/Chemical Name: 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide
InChi Key: YIDDLAAKOYYGJG-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H24FN7O/c1-14(2)32-13-27-30-23(32)19-5-4-6-22(28-19)29-24(33)17-10-21(15(3)9-18(17)25)31-11-20(26-12-31)16-7-8-16/h4-6,9-14,16H,7-8H2,1-3H3,(H,28,29,33)
SMILES Code: O=C(NC1=NC(C2=NN=CN2C(C)C)=CC=C1)C3=CC(N4C=C(C5CC5)N=C4)=C(C)C=C3F
Appearance: White to off-white
Purity: >98% (Note: HPLC, LC/MS may detect up to ~ 5% tautomer depending on methods/conditions used).
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Selonsertib is an ASK1 inhibitor with a pIC50 of 8.3. |
| In vitro activity: | The treatment combination of selonsertib with antineoplastic drugs has potential to counter multidrug resistance (MDR) in cancer cells overexpressing ABCB1 or ABCG2. This study investigated selonsertib for its potential to reverse MDR mediated by ABC transporters. Selonsertib effectively reversed MDR associated with ABCB1 and ABCG2 but not ABCC1 or ABCC10. Selonsertib stimulated ATPase activity in ABCB1 and ABCG2 and exhibited interactions with their substrate-binding sites. Reference: Cancer Lett. 2019 Jan;440-441:82-93. https://pubmed.ncbi.nlm.nih.gov/30315846/ |
| In vivo activity: | Selonsertib may reduce liver fibrosis in patients with nonalcoholic steatohepatitis and stage 2-3 fibrosis. After 24 weeks of treatment, the proportion of patients with a one or more stage reduction in fibrosis in the 18-mg selonsertib group was 13 of 30 (43%) and in the 6-mg selonsertib group, 8 of 27 (30%). Improvement in fibrosis was associated with reductions in liver stiffnessy and collagen content and lobular inflammation, and improvements in serum biomarkers of apoptosis and necrosis. Reference: Hepatology. 2018 Feb;67(2):549-559. https://pubmed.ncbi.nlm.nih.gov/28892558/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 20.5 | 46.02 |
The following data is based on the product molecular weight 445.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Lee JH, Ji SH, Lim JS, Ahn S, Yun HY, Kim SH, Song JS. Anti-neuroinflammatory Effects and Brain Pharmacokinetic Properties of Selonsertib, an Apoptosis signal-regulating Kinase 1 Inhibitor, in mice. Neurochem Res. 2022 Dec;47(12):3829-3837. doi: 10.1007/s11064-022-03777-9. Epub 2022 Oct 30. PMID: 36309631. 2. Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, Shukla S, Ambudkar SV, Kong D, Chen ZS. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. Cancer Lett. 2019 Jan;440-441:82-93. doi: 10.1016/j.canlet.2018.10.007. Epub 2018 Oct 10. PMID: 30315846; PMCID: PMC8132112. 3. Badal SS, Al Tuhaifi T, Yu YF, Lopez D, Plato CT, Joly K, Breckenridge DG, Yang HC, Liles JT, Fogo AB. Selonsertib Enhances Kidney Protection Beyond Standard of Care in a Hypertensive, Secondary Glomerulosclerosis CKD Model. Kidney360. 2022 Apr 18;3(7):1169-1182. doi: 10.34067/KID.0001032022. PMID: 35919527; PMCID: PMC9337896. 4. Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR; GS-US-384-1497 Investigators. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018 Feb;67(2):549-559. doi: 10.1002/hep.29514. Epub 2017 Dec 26. Erratum in: Hepatology. 2018 May;67(5):2063. PMID: 28892558; PMCID: PMC5814892. |
| In vitro protocol: | 1. Lee JH, Ji SH, Lim JS, Ahn S, Yun HY, Kim SH, Song JS. Anti-neuroinflammatory Effects and Brain Pharmacokinetic Properties of Selonsertib, an Apoptosis signal-regulating Kinase 1 Inhibitor, in mice. Neurochem Res. 2022 Dec;47(12):3829-3837. doi: 10.1007/s11064-022-03777-9. Epub 2022 Oct 30. PMID: 36309631. 2. Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, Shukla S, Ambudkar SV, Kong D, Chen ZS. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. Cancer Lett. 2019 Jan;440-441:82-93. doi: 10.1016/j.canlet.2018.10.007. Epub 2018 Oct 10. PMID: 30315846; PMCID: PMC8132112. |
| In vivo protocol: | 1. Badal SS, Al Tuhaifi T, Yu YF, Lopez D, Plato CT, Joly K, Breckenridge DG, Yang HC, Liles JT, Fogo AB. Selonsertib Enhances Kidney Protection Beyond Standard of Care in a Hypertensive, Secondary Glomerulosclerosis CKD Model. Kidney360. 2022 Apr 18;3(7):1169-1182. doi: 10.34067/KID.0001032022. PMID: 35919527; PMCID: PMC9337896. 2. Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR; GS-US-384-1497 Investigators. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018 Feb;67(2):549-559. doi: 10.1002/hep.29514. Epub 2017 Dec 26. Erratum in: Hepatology. 2018 May;67(5):2063. PMID: 28892558; PMCID: PMC5814892. |
1: Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, Shukla S, Ambudkar SV, Kong D, Chen ZS. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. Cancer Lett. 2019 Jan;440-441:82-93. doi: 10.1016/j.canlet.2018.10.007. Epub 2018 Oct 10. PubMed PMID: 30315846.
2: Nelson CH, Wang L, Fang L, Weng W, Cheng F, Hepner M, Lin J, Garnett C, Ramanathan S. A Quantitative Framework to Evaluate Proarrhythmic Risk in a First-in-Human Study to Support Waiver of a Thorough QT Study. Clin Pharmacol Ther. 2015 Dec;98(6):630-8. doi: 10.1002/cpt.204. Epub 2015 Sep 29. PubMed PMID: 26259519.
3: Lin JH, Zhang JJ, Lin SL, Chertow GM. Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129(1):29-33. doi: 10.1159/000369152. Epub 2014 Dec 17. PubMed PMID: 25531162.
